Idorsia Pharmaceuticals Ltd: Idorsia announces financial results for the first quarter 2023 - QUVIVIQ now the leading branded insomnia medicine in the commercial market in the US

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - April 25, 2023 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2023. Commercial highlights QUVIVIQ

Related Keywords

United States ,Japan ,Germany ,France ,Allschwil ,Switzerland General ,Switzerland ,Canada ,Spain ,United Kingdom ,Italy ,Mochida ,Miyazaki ,Japanese ,Great Britain ,Swiss ,Messe Basel ,Neurocrine Biosciences ,Andrewc Weiss ,Schweizerisches Handelsamtsblatt ,Johnson ,Simon Jose ,Jean Paul Clozel ,Head Of Investor Relations Corporate Communications ,Regulatory Agency ,Company Annual ,Mochida Pharmaceutical Co Ltd ,Idorsia Ltd ,Day Center ,Congress Center ,Health Canada ,Swiss Exchange ,European Commission ,United States Drug Enforcement Administration ,Idorsia Pharmaceuticals Ltd ,International Study ,Neurocrine Biosciences Inc ,Scripts National Preferred Formulary ,Swiss Exchange On ,Paul Clozel ,Chief Executive Officer ,Chief Financial Officer ,Express Scripts National Preferred Formulary ,Tricare Uniform Formulary ,Citizen Petition ,Controlled Substances ,Full Prescribing Information ,Medication Guide ,Chief Commercial Officer ,Product Characteristics ,Patient Information ,Healthcare Professionals ,Economic Burden ,Janssen Biotech ,Annual General Meeting ,Annual Report ,Swiss Official Gazette ,Compensation Report ,Results Day Center ,General Meeting ,Vice President ,Investor Relations ,Pharmaceuticals Ltd ,Idorsia ,Pharmaceuticals ,Nnounces ,Financial ,Results ,First ,Quarter ,023 ,Quviviq ,Reading ,Tranded ,Insomnia ,Medicine ,Commercial ,Market ,